A new report says GLP-1 weight loss drugs drove a 34.1% drop in bariatric surgery volumes as semaglutide reshapes how hospitals generate revenue.
A new report by Wells Fargo spotlights how GLP-1 weight loss drugs are reshaping the healthcare industry by addressing obesity.
Wells Fargo released a report Thursday which notes that much of the Am… [+3775 chars]
Discussion (0)
No comments yet. Be the first to share your thoughts!
Join the Conversation
You need to be logged in to leave a comment.
Sign In Create Account